Fanhua Announces Grant of Share Options to Key Employees
July 08, 2024 07:09 ET
|
Fanhua Inc.
GUANGZHOU, China, July 08, 2024 (GLOBE NEWSWIRE) -- Fanhua Inc. (Nasdaq: FANH) (the “Company” or “Fanhua”), a leading independent technology-driven financial services provider in China, today...
HOOKIPA Pharma Announces Effective Date of 1-for-10 Reverse Stock Split
July 08, 2024 07:01 ET
|
HOOKIPA Pharma Inc.
NEW YORK and VIENNA, July 08, 2024 (GLOBE NEWSWIRE) -- HOOKIPA Pharma Inc. (NASDAQ: HOOK, “HOOKIPA”), a company developing a new class of immunotherapeutics based on its proprietary arenavirus...
Bitfarms Appoints Ben Gagnon as Chief Executive Officer
July 08, 2024 07:00 ET
|
Bitfarms Ltd.
This news release constitutes a “designated news release” for the purposes of the Company’s prospectus supplement dated March 8, 2024, to its short form base shelf prospectus dated November 10, 2023. ...
AFC Gamma Reconfirms Completion Date of Spin-Off of Commercial Real Estate Portfolio
July 08, 2024 07:00 ET
|
AFC Gamma, Inc.
Record Date for Distribution of Sunrise Realty Trust to be July 8, 2024Distribution Date to be July 9, 2024 WEST PALM BEACH, Fla., July 08, 2024 (GLOBE NEWSWIRE) -- AFC Gamma, Inc. (NASDAQ:AFCG)...
Creative Realities added to membership of Russell Microcap® Index
July 08, 2024 07:00 ET
|
Creative Realities
Creative Realities added to membership of Russell Microcap® Index
Nurix Therapeutics to Participate in the UBS Virtual Targeted Protein Degradation (TPD) Day
July 08, 2024 07:00 ET
|
Nurix Therapeutics, Inc.
SAN FRANCISCO, July 08, 2024 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical stage biopharmaceutical company developing targeted protein modulation drugs designed to treat...
iTeos gibt Dosierung des ersten Patienten in der Phase-III-Studie GALAXIES Lung-301 bekannt und erhält Meilensteinzahlungen in Höhe von 35 Mio. USD von GSK
July 08, 2024 07:00 ET
|
iTeos Therapeutics Inc.
WATERTOWN, Massachusetts. und GOSSELIES, Belgien, July 08, 2024 (GLOBE NEWSWIRE) -- iTeos Therapeutics, Inc. (Nasdaq: ITOS) („iTeos“), ein in klinischen Stadium tätiges Biopharmazieunternehmen, das...
iTeos annonce la prise en charge du premier patient de l'étude de phase 3 GALAXIES Lung-301 et l'obtention de versements d'étapes de 35 millions de dollars de la part de GSK
July 08, 2024 07:00 ET
|
iTeos Therapeutics Inc.
WATERTOWN, Massachusetts et GOSSELIES, Belgique, 08 juill. 2024 (GLOBE NEWSWIRE) -- iTeos Therapeutics, Inc. (Nasdaq : ITOS) (« iTeos »), une société biopharmaceutique au stade clinique, pionnière...
Sunrise Realty Trust Invests $14.1 Million in Senior Loan for an Austin Multi-Family Development
July 08, 2024 07:00 ET
|
Sunrise Realty Trust, Inc.
WEST PALM BEACH, Fla., July 08, 2024 (GLOBE NEWSWIRE) -- Sunrise Realty Trust, Inc. (“SUNS” or the “Company”), an institutional commercial real estate lender focused on the Southern United States,...
Lexeo Therapeutics Appoints Tim Van Hauwermeiren to its Board of Directors
July 08, 2024 07:00 ET
|
Lexeo Therapeutics
Lexeo Therapeutics Appoints Tim Van Hauwermeiren to its Board of Directors